Searched for
DRUG PRICE CONTROL
Protect patients and patents smartlyThe Kerala High Court has stressed the importance of making cancer medicines like ribociclib more affordable for patients. The Government o...- Jefferies lists 6 factors that will shape CRDMO winners; Divi’s Labs, Sai Life, Laurus, Anthem among stocks to watchIndia's CRDMO sector is on the brink of expansion, backed by solid partnerships with major pharmaceutical players and comprehensive capabil...
- Panel to finalise cancer drugs for 30% trade margin cap; Rs 2,500 crore annual savings possibleAn expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduc...
- SC asks govt to broaden inflated pricing review beyond oncologyThe Supreme Court has asked the government to address high markups on medicines and medical devices. The court questioned the decision to l...
- Supreme Court questions govt over drug pricing, asks why cap limited to anti-cancer medicinesThe Supreme Court expressed its worry over the government's restriction of price control measures to only anti-cancer drugs, questioning wh...
- Cancer drugs may get up to 70% cheaper as govt fixes trade margins on non-scheduled medicines at 30%The government is aiming to cap trade margins on anti-cancer medications at 30%. An expert committee has been tasked with compiling a repor...
- Form panel to curb pharma freebies: SCThe Supreme Court has ordered the government to establish a committee to investigate unethical pharmaceutical marketing. The committee is t...
- Govt set to cap trade margins on more cancer drugs before SC hearingThe Indian government plans to announce a new list of cancer drugs for trade margin rationalisation today. Union Health Minister JP Nadda w...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsIn the short term, be ready for volatility, and do not mistake the passing of one big event for an all-clear. In the long term, give up try...
- When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...
- Michigan is a battleground in 2026: An open Senate seat after Sen. Gary Peters' retirement has both parties fighting for it all in US midterm electionsMichigan's open Senate seat becomes highly contested with Democrat Abdul El-Sayed and Republican Mike Rogers. El-Sayed focuses on healthcar...
- US midterm elections 2026: Trump's approval rating falls to record low as 2026 Midterms nearPresident Trump's approval rating has reached a low of 31% according to a recent poll. Concerns about the economy and rising prices were hi...
- Karnataka flags 52x mark-up on cancer drugs, seeks Centre's interventionKarnataka conducted inspections revealing significant price disparities between hospital procurement and patient billing for cancer drugs a...
- Jefferies picks 6 hospitals as Buy after steep correction offers 'excellent' entry points. Check target priceJefferies has maintained a Buy rating on six hospital stocks, including Apollo Hospitals and Fortis Healthcare, following a sharp correctio...
- Hospital stocks fall up to 6%: Apollo, Fortis, KIMS tumble as SC questions drug mark-upsHospital stocks came under pressure after the Supreme Court raised concerns over steep mark-ups on medicines sold through corporate hospita...
- SC seeks 16% MRP cap on medicines, flags huge cancer drug markupsThe Supreme Court has raised concerns regarding inflated prices of essential medicines, particularly cancer drugs, sold at exorbitant marku...
- Cancer drug costs Rs 2,700, sells for Rs 27,000: SC questions 10x markup at hospitalsThe Supreme Court has questioned steep markups on cancer drugs and asked the Centre to examine a uniform 16% margin on all medicines. The c...
- Kerala HC says exorbitant drug prices can trigger government intervention in patented medicinesThe Kerala High Court ruled that government intervention is permissible for prohibitively priced patented medicines. The court directed the...
- Sun Pharma signs major deal with LIB Therapeutics of US, gains access to $3.7-bn global market for bad cholesterol inhibitor PCSK9Sun Pharma has signed an exclusive agreement with LIB Therapeutics for Lerodalcibep, a cholesterol-lowering medication. This deal covers al...
- 'Inflated medicine prices are daylight robbery': SC pulls up pharma companies over huge MRP-PTR gapSupreme Court on Tuesday questioned the wide gap between the price to retailer and MRP of some cancer medicines, calling inflated pricing a...
Load More
